Effects of spironolactone in hypokalemic CAPD patients

Phase 3

Active, not recruiting

• Conditions: end stage renal disease patients on CAPD; CAPD; Hypokalemia; spironolactone; serum potassium

• Registration Number: TCTR20130314001
• Lead Sponsor: Burapha University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-03-14
• Study Completion: 2013-05-29
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. ESRD patients on CAPD
2. history of hypokalemia

Exclusion Criteria

1. history of hyperkalemia
2. participation in interventional study in the previous 3 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
serum potassium every two weeks serum potassium Milliequivalent per litre

Secondary Outcome Measures

Name	Time	Method
potassium excretion rate at the end of treatment daily potassium excretion in urine and dialysate,dose of potassium replacement every two weeks dose of oral potassium replacement